查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球主動脈內反搏裝置市場 - 2023-2030
市場調查報告書
商品編碼
1373393

全球主動脈內反搏裝置市場 - 2023-2030

Global Intra-Aortic Counterpulsation Device Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 170 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

主動脈內反搏裝置是一種旨在幫助心臟更有效地泵血的醫療設備。它主要用於治療嚴重的心臟疾病，特別是心臟衰竭、心因性休克或某些心臟手術期間。該裝置的工作原理是調整主動脈（將含氧血液從心臟輸送到身體的主要動脈）中的血流時間。

主動脈內反搏裝置有多種類型，但最受歡迎的是主動脈內球囊反搏器和主動脈內插管。這些設備對於危重心臟疾病至關重要，因為它們可以改善血流和冠狀動脈灌注。

市場動態：促進因素

全球心臟病發病率的不斷上升預計將推動市場成長

根據世界心臟聯合會的數據，全球心血管疾病(CVD) 死亡人數從1990 年的1210 萬人激增至2021 年的2050 萬人。CVD 是一組心臟和血管疾病，包括冠心病、腦血管疾病、風濕性心臟病疾病和其他狀況。超過五分之四的 CVD 死亡是由於心臟病發作和中風造成的，其中三分之一的死亡發生在 70 歲以下的人群中。

IACD 對於治療急性心臟病至關重要，因為它們有助於增加心輸出量並改善冠狀動脈血流量。在心臟病發作或嚴重心臟衰竭等情況下，IACD 可以暫時緩解心臟壓力，減輕壓力並支持重要器官灌注。因此，由於心血管疾病（CVD）相關死亡人數的上升以及病例的複雜性不斷增加，對 IACD 的需求不斷成長。這些設備可以成為重症患者的生命線，有可能降低死亡率並提高照護品質。

因此，醫療保健提供者越來越認知到其挽救生命的潛力，並將其涵蓋治療策略，這推動了 IACD 市場的成長。此外，人口老化的加劇和高風險心臟手術數量的增加預計將在預測期內推動市場發展。

市場動態： 限制：

主動脈內反搏裝置的市場可能會因產品召回、高成本、熟練操作人員短缺和潛在併發症而受到阻礙。

目錄

第 1 章：方法與範圍

  • 研究方法論
  • 報告的研究目的和範圍

第 2 章：定義與概述

第 3 章：執行摘要

  • 按產品類型分類
  • 按指示顯示的片段
  • 最終使用者的片段
  • 按地區分類

第 4 章：動力學

  • 影響因素
    • 促進要素
      • 全球心臟病發作率不斷上升
    • 限制
      • 增加產品召回
    • 機會
    • 影響分析

第 5 章：產業分析

  • 波特五力分析
  • 供應鏈分析
  • 定價分析
  • 監管分析
  • 管道分析
  • 專利分析
  • DMI 意見

第 6 章：COVID-19 分析

  • COVID-19 分析
    • 新冠疫情爆發前的情景
    • 新冠疫情期間的情景
    • 新冠疫情後的情景
  • COVID-19 期間的定價動態
  • 供需譜
  • 疫情期間政府與市場相關的舉措
  • 製造商策略舉措
  • 結論

第 7 章：按產品類型

  • 主動脈內球囊反搏 (IABP)
  • 主動脈內插管

第 8 章：依指示

  • 心肌梗塞
  • 心臟休克
  • 心臟衰竭
  • 其他

第 9 章：最終用戶

  • 醫院
  • 門診手術中心
  • 專業心臟中心
  • 其他

第 10 章：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 歐洲其他地區
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 亞太
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 亞太其他地區
  • 中東和非洲

第 11 章：競爭格局

  • 競爭場景
  • 市場定位/佔有率分析
  • 併購分析

第 12 章：公司簡介

  • Teleflex Incorporated
    • 公司簡介
    • 產品組合和描述
    • 財務概覽
    • 主要進展
  • Getinge
  • Zeon Medical Inc.
  • Abiomed, Inc.

第 13 章：附錄

簡介目錄
Product Code: MD7354

Overview

Intra-aortic counterpulsation device is a medical device designed to help the heart pump blood more effectively. It is mainly used to manage severe heart conditions, especially heart failure, cardiogenic shock, or during certain cardiac procedures. The device works by adjusting the timing of blood flow in the aorta the primary artery that carries oxygenated blood from the heart to the body.

There are various types of intra-aortic counterpulsation devices, but the intra-aortic balloon pump and intra-aortic cannula are the most popular. These devices are crucial in critical cardiac conditions as they improve blood flow and coronary artery perfusion.

Market Dynamics: Drivers

The increasing prevalence of heart attacks worldwide is expected to drive market growth

According to the World Heart Federation, deaths from cardiovascular disease (CVD) surged globally from 12.1 million in 1990 to 20.5 million in 2021. CVDs are a group of disorders of the heart and blood vessels and include coronary heart disease, cerebrovascular disease, rheumatic heart disease, and other conditions. More than four out of five CVD deaths are due to heart attacks and strokes, and one-third of these deaths occur prematurely in people under 70 years of age.

IACDs are essential in managing acute cardiac conditions as they help increase cardiac output and improve coronary blood flow. In scenarios like heart attacks or severe heart failure, IACDs can provide temporary relief to the heart, reducing strain, and supporting vital organ perfusion. Therefore, due to the rising prevalence of cardiovascular disease (CVD)-)-related fatalities and the increasing complexity of cases, there is a growing demand for IACDs. These devices can be a lifeline for patients in critical conditions, potentially reducing mortality rates and enhancing the quality of care.

As a result, healthcare providers are increasingly recognizing their lifesaving potential and incorporating them into their treatment strategies, which is driving growth in the IACD market. Furthermore, the growing aging population and an increasing number of high-risk cardiac procedures are the factors expected to drive the market over the forecast period.

Market Dynamics: Restraint:

The market for intra-aortic counterpulsation devices may be hindered by product recalls, high costs, shortage of skilled operators, and potential complications.

Segment Analysis

The global intra-aortic counterpulsation device market is segmented based on product type, surgical approach, technology, end-user and region.

The Intra-Aortic Balloon Pump (IABP) from the Product Type Segment Accounted for Approximately 47.8% of the Coagulation Analyzers Market Share

The Intra-Aortic Balloon Pump (IABP) is a medical device used to assist the heart in pumping blood more effectively. It is primarily employed in the management of patients with severe heart conditions, particularly those experiencing heart failure, cardiogenic shock, or undergoing certain cardiac procedures. The device operates by altering the timing of blood flow within the aorta, the main artery that carries oxygenated blood from the heart to the rest of the body.

Moreover, owing to the increasing prevalence of cardiovascular diseases, and the growing aging population are the factors expected to drive the market over the forecast period.

For instance, according to the Journal of Heart Association Article 2022, the global burden of cardiovascular disease is increasing, especially among older adults. The most common diseases in this demographic are congestive heart failure, coronary artery diseases, hypertension, atrial fibrillation, peripheral arterial disease, valvular heart disease, and stroke. Older adults with cardiovascular disease have complex and severe conditions due to comorbidities and geriatric syndromes, which puts them at higher risk of functional decline and complications.

Therefore, IABPs are essential in providing temporary support for older adults who suffer from advanced cardiovascular conditions, serving as a crucial bridge to more definitive treatments such as coronary interventions or cardiac surgeries. These devices help stabilize patients, optimize their condition, and improve their readiness for surgical procedures.

Moreover, IABPs can significantly improve the overall prognosis of older adults with cardiovascular disease. By reducing the workload on the heart and enhancing cardiac output, these devices contribute to better outcomes and increase the chances of survival. Hence, owing to the above factors, the market segment is expected to hold the largest market share over the forecast period.

Geographical Analysis

North America Accounted for Approximately 39.8% of the Market Share in 2022

North America region is expected to hold the largest market share over the forecast period owing to the increasing prevalence of myocardial infarction, and growing cardiac surgeries. For instance, according to the Society of Thoracic Surgeons (STS) National Adult Cardiac Surgery Database reported that in 2021, there were approximately 5,048 total cardiac surgeries performed. Therefore, there is an increase in demand for Intra-Aortic Counterpulsation Devices (IACDs) may increase due to the positive impact of the total number of cardiac surgeries.

In contrast, the market is being negatively affected by product recalls. One such example is the Class I level recall in the U.S. by Teleflex, which involved the Arrow AutoCAT 2 and AC3 Optimus intra-aortic balloon pumps. The recall was due to a potential breakdown of motor connector wires.

Competitive Landscape

The major global players in the intra-aortic counterpulsation device market include: Teleflex Incorporated, Getinge, Zeon Medical Inc., and Abiomed, Inc. among others.

COVID-19 Impact Analysis:

The COVID-19 pandemic has had a significant effect on cardiac surgery worldwide. Many hospitals have had to reduce or suspend non-emergency surgeries, including cardiac surgeries, to conserve resources for COVID-19 patients. This has reduced the number of surgeries performed and the backlog of patients waiting for surgery. As per the article published in the Archives of Cardiovascular Diseases in 2021, cardiac surgery systematically requires postoperative intensive care. As these specialized units were reserved for patients with COVID-19 necessitating respiratory support, elective open-heart surgeries were substantially delayed in almost all french centers.

Furthermore, some cardiac patients may be at a higher risk of severe illness from COVID-19 due to underlying heart conditions, which may make them more hesitant to seek treatment. The pandemic also decreased the number of patients admitted to hospitals for heart attacks, which is believed to be due to people being afraid to seek medical attention out of fear of getting COVID-19. This decreased hospital revenue, resulting in some downsizing of services, including cardiac services.

Overall, the COVID-19 pandemic has had a significant impact on cardiac surgery worldwide, leading to a decrease in the number of surgeries being performed and a backlog of patients waiting for surgery, as well as affecting the availability of medical staff and equipment and leading to a decrease in revenue for hospitals.

Why Purchase the Report?

  • To visualize the global intra-aortic counterpulsation device market segmentation based on product type, indication, end-user and region as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development
  • Excel data sheet with numerous data points of intra-aortic counterpulsation device market-level with all segments
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study
  • Product mapping available as excel consisting of key products of all the major players

The global intra-aortic counterpulsation device market report would provide approximately 43 tables, 52 figures, and 170 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Indication
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The increasing prevalence of heart attacks worldwide
    • 4.1.2. Restraints
      • 4.1.2.1. Increasing product recalls
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Pipeline Analysis
  • 5.6. Patent Analysis
  • 5.7. DMI Opinion

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID
    • 6.1.2. Scenario During COVID
    • 6.1.3. Scenario Post COVID
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. By Product Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 7.1.2. Market Attractiveness Index, By Product Type
  • 7.2. Intra-Aortic Balloon Pump (IABP)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Intra-Aortic Cannula

8. By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Myocardial Infarction*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Cardiogenic Shock
  • 8.4. Heart Failure
  • 8.5. Others

9. By End User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.1.2. Market Attractiveness Index, By End User
  • 9.2. Hospitals*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Ambulatory Surgical Centers
  • 9.4. Specialty Heart Centers
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. UK
      • 10.3.6.3. France
      • 10.3.6.4. Spain
      • 10.3.6.5. Italy
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

  • 11.1. Competitive Scenario
  • 11.2. Market Positioning/Share Analysis
  • 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

  • 12.1. Teleflex Incorporated*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
  • 12.2. Getinge
  • 12.3. Zeon Medical Inc.
  • 12.4. Abiomed, Inc.

LIST NOT EXHAUSTIVE

13. Appendix

  • 13.1. About Us and Services
  • 13.2. Contact Us